SThis report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this hallucinogenic drug in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.